cyrilzakka/clinical-trials huggingface dataset:
Adrenal Artery Ablation for Uncontrolled Hypertension

The activation of the renin-angiotensin-aldosterone system (RAAS) plays a key role in uncontrolled hypertension or resistant hypertension. Surgery and and medicine are the main treatment for primary aldosteronism(PA) by the current guidelines. However, only a small part of patients with PA meet the surgical criteria, and most of patients with uncontrolled hypertension and activation of RAAS have to take spironolactone or other antihypertensive drugs for long time. On the other side, long-term inhibition of aldosterone receptor may cause hyperkalemia, male breast hyperplasia and other adverse reactions. Moreover, hyperaldosterone is still not corrected by spironolactone, which causes extensive cerebrovascular damages even though blood pressure and blood potassium had been normalized.

With the development of adrenal vein sampling and adrenal ablation, selective arterial ablation of adrenal gland(AAA) was observed with significant decrease of blood aldosterone and blood pressure in patients with PA, which made it promising that uncontrolled hypertension could be relieved by selective AAA.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged between 30-60 years old.
* Patients with poorly controlled hypertension (office blood pressure ≥130/80 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d) for at least 2 weeks
* Positional blood aldosterone ≥100pg/ml.
* Informed consent signed and agreed to participate in this trial.

Exclusion Criteria:

* Hyperkalemia or hypokalemia.
* Secondary hypertension.
* History of depression, schizophrenia or vascular dementia.
* Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.
* Adrenergic insufficiency.
* Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
* Acute infections, tumors and severe arrhythmias, psychiatric disorders,
* drugs or alcohol addicts.
* Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
* Fertile woman without contraceptives.
* Coagulation dysfunction.
* Pregnant women or lactating women.
* Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
* Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.
* Allergy or any contraindications for the study drugs, contrast agents and alcohol.
* Refused to sign informed consent
Ischemic Preconditioning Claudication Study

This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication.

This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication. Peripheral arterial disease (PAD) is a circulatory condition in which large supply blood vessels narrow, reducing oxygen and nutrient distribution to peripheral tissues. IPC protects against tissue damage caused by ischemia and can improve functional capacity in patients recovering from stroke; however, the benefit of ischemic preconditioning in patients with peripheral arterial disease remains unclear.

The investigators predict that ischemic preconditioning (IPC) will delay claudication onset time (COT), increase peak walking time (PWT) and improve muscle strength in patients with intermittent claudication.

The investigators will determine whether IPC improves claudication onset time (COT) and peak walking time (PWT) in patients with intermittent claudication. A motorized treadmill will be employed to assess COT and PWT.

The investigators will determine whether IPC can improve muscle strength and time to pain onset in the affected leg of patients with intermittent claudication. These metrics will be assessed quantitatively using a Biodex™ dynamometer.

Eligibility Criteria:
Inclusion Criteria:

1. between ages of 18-80
2. able to give informed consent
3. presence of vascular disease with intermittent claudication

Exclusion Criteria:

1. age \< 18 or \>80
2. unable to give informed consent
3. presence of vascular disease with leg pain at rest, ischemic ulceration, or gangrene
4. pregnancy
5. unable to walk on a treadmill
6. unable to perform or tolerate ischemic preconditioning
7. unable to follow commands
8. exercise capacity limited by symptoms of angina, congestive heart failure, chronic obstructive pulmonary disease, or arthritis to be determined by PI
9. patients who have undergone vascular surgery or endovascular surgery in the previous year on the affected leg
10. history of major lower extremity amputation
11. history of major psychiatric disorder
12. history of uncontrolled hypertension
Keratoconus Detection by Ultrasound

Keratoconus (KC) is a corneal disease which will in many cases ultimately require corneal transplantation to maintain vision. Early detection, which is not possible with current technology, would allow early treatment and prevent severe damage to KC corneas inadvertently operated upon for correction of vision. The investigators' aim is to combine measurements of different properties of the cornea to develop means for early detection of KC.

Keratoconus is the most common degenerative disease affecting the cornea. As keratoconus develops, the cornea thins and bulges. Eventually, a corneal transplant may be needed to maintain vision. In its earliest stages, the disease is particularly difficult to detect. This is of great importance to the corneal refractive surgeon because surgical treatment of a keratoconic cornea will weaken it and greatly accelerate the occurrence of symptoms. Early detection of keratoconus will benefit patients because of the recent development of methods for strengthening the corneal stroma and preventing disease progression.

The investigators have developed a technique based on the use of high resolution ultrasound for imaging the cornea and measuring the thickness of its component layers, including the epithelium and the stroma. In early keratoconus, as the anterior stromal surface begins to bulge forward, the epithelium will thin above the apex of the bulge and thicken around it, to maintain a smooth anterior surface. The investigators have also developed methods for characterizing the elastic properties of the cornea by inducing and measuring surface displacements in response to a pulse of acoustic radiation force.

The investigators' goal is to reduce the percentage of screened cases deemed keratoconus-suspect by at least a factor of two by allowing an unambiguous diagnosis of early keratoconus. This would provide two major benefits; (1) to be able to predict eyes with higher risk of developing ectasia after corneal refractive surgery, and (2) early diagnosis would allow earlier treatment of the condition with collagen crosslinking, preserving the cornea from disease progression.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of keratoconus (KC) or keratoconus-suspect
* Blood relation of person with KC
* Age-matched normal of KC subjects
* Ability to sit still in front of ultrasound unit and lie on exam table

Exclusion Criteria:

* Other eye disease
Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome

It is Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome


Eligibility Criteria:
Inclusion Criteria:

* cases of PCO

Exclusion Criteria:

* amenorrhea
* womenwho had previous IVF
C-reactive Protein Levels in Acute Apical Abscess Due to Root Canal Infection

C-reactive protein levels of patients with acute apical abscess are evaluated before and after root canal treatment

In patients with acute apical abscess C-reactive proteins are evaluated before and after root canal treatment. In this intra-canal medications calcium hydroxide and triple antibiotic paste are compared. PAI score of the corresponding tooth is noted .

Eligibility Criteria:
Inclusion Criteria:

patient with acute apical abscess

Exclusion Criteria:

* Teeth with evidence of previous initiated root canal treatment
* History of myocardial infarction, coronary heart disease
* Patients allergic to local anesthetic
* Patients under steroid medication
* Patients who are immunocompromised
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).


Eligibility Criteria:
Inclusion Criteria:

* Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label.
* Participants for whom the physician has decided to initiate CLL treatment with venetoclax.
* Participants who have been informed verbally and in writing about this study, and who do not object to their data being processed or subjected to data quality control.

Exclusion Criteria:

- Participants currently participating (or previously participated) in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients

For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.

The aim of this pilot study is to examine global and regional LV systolic and diastolic function, cardiac output, cardiac reserve, VO2peak and CVD risk profile in males recently diagnosed with testicular cancer treated with surgery alone or surgery and chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* surgery and surveillance
* surgery and multi-cycle chemotherapy
* both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors
* Karnofsky performance index \> 70%
* no contraindications to cardiopulmonary testing

Exclusion Criteria:

* documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.
Prospective Cohort of Respiratory Insufficiency Outcome

The Respiratory Insufficiency Outcome (RIO) project consists in a french multicenter prospective cohort of patients with chronic obstructive pulmonary disease (COPD) undergoing domiciliary noninvasive positive pressure ventilation.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of COPD
* domiciliary noninvasive ventilation

Exclusion Criteria:

* noninvasive ventilation set up for a neuromuscular disease
Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes

The purpose of this study is to examine whether the value of vaginal fluid cytokine levels as well as computerized fetal ECG analysis are suitable clinical parameters to detect an imminent intra-amniotic inflammation with a high risk of fetal inflammatory response syndrome (FIRS) or a neonatal early onset sepsis (EOS) and whether these parameters can be determined on a daily basis in the clinical monitoring of pregnancies complicated by PPROM.

Preterm premature rupture of membranes (PPROM) is one of the leading causes for preterm birth and adverse neonatal outcome. Between 24 0/7 and 34 0/7 weeks of gestation the prolongation of pregnancy is the recommended course of action to reduce the risks of prematurity in most countries. An intra-amniotic infection resulting in fetal inflammatory response syndrome (FIRS) or early onset neonatal sepsis (EOS) is often associated with high morbidity and mortality.

Standard monitoring includes the maternal response to inflammation (i.e. maternal serum parameters) as well as fetal signs of acute FIRS (i.e. fetal tachycardia, high cytokine level in amniotic fluid obtained by amniocentesis). Changes of fetal ECG-parameters are also a sign of an acute FIRS.

Currently, there is no adequate parameter for the surveillance of a possible ongoing intra-amniotic infection. Other studies have reported a correlation between vaginal fluid interleukine 6 (IL6) collected noninvasively and the risk of FIRS and EOS. Information obtained by computerized fetal ECG analysis might be suitable to detect early signs of fetal infection before the manifestation of FIRS.

With the implementation of a vaginal fluid collector it is possible to detect the vaginal fluid cytokine in clinical everyday routine. With the improvement of fetal ECG monitoring it is possible to record the fetal ECG daily. This study examines the correlation between these new parameters and the onset of fetal infection before the manifestation of a severe systemic fetal inflammation.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of preterm rupture of the fetal membranes
* Pregnancy between 24 0/7 and 34 0/7 weeks of gestation
* Ability to give informed consent in german or english

Exclusion Criteria:

* Sign of acute amniotic infection syndrome
* independent indication for urgent delivery
* Active labor
* Missing informed consent
The Effect of Square Dance on Rheumatoid Arthritis

The purpose of this study is to observe the effect of square dance on rheumatoid arthritis.


Eligibility Criteria:
Inclusion Criteria:

* had wrist and/or MCP involvement
* aged 18 years diagnosed by rheumatology consultants with RA

Exclusion Criteria:

* severe psychological difficulties
* currently receiving mental health care
* any medical condition that might prevent them from safely exercising (e.g. history of more severe heart, lung or cerebrovascular disease)
* previously attended an education programme
* had a Modified Health Assessment Questionnaire score above 2 (0-3)
Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

To learn if MRS can effectively assess spinal cord lesions.

Primary Objective:

Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at different TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade.

Secondary Objective:

Test success of the spectrum by implementing the protocol on 3 patients with spinal LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.

Eligibility Criteria:
Inclusion Criteria:

Volunteers:

* Adults \> 18 years
* Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
* Consent able patients.

Patients with high risk for LMD to receive prophylactic CNS radiation:

* Adults \> 18 years old.
* MR or CSF without evidence of LMD.
* Patients with high risk for LMD to receive CSI as part of standard treatment of prophylactic LMD disease.
* Consent able patients, willingness and ability to comply with the study procedures.
* No spinal cord lesions.

Exclusion Criteria:

Volunteers:

* Age \< 18 years
* Pregnant or breastfeeding individuals.
* History of cancer.
* History of spinal cord lesions including malignant, demyelinating, or inflammatory.
* History of prior spinal surgery.
* History of implantable devices.
* History of MR claustrophobia.
* Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
* Scoliosis.

Patients with high risk for spinal LMD:

* Age \< 18 years
* History of spinal cord lesions including malignant, demyelinating, or inflammatory.
* History of prior spinal surgery.
* History of implantable devices.
* History of MR claustrophobia.
* Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
* Scoliosis.
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

The objective of this study is to evaluate the efficacy and safety of intravenous micafungin for the treatment of proven or probable fungal infections caused by Aspergillus sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are diagnosed as proven or probable infections caused by aspergillus (including fungemia, respiratory mycosis and gastrointestinal mycosis) with reference to the definition of EORTC/MSG
* Females of childbearing potential are not pregnant in the study and reliable methods of contraception should be maintained during the whole study.
* Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study is obtained.

Exclusion Criteria:

* Patient received any echinocandins drug within 1 month prior to enrollment.
* Patient was enrolled in any other clinical study within the last month.
* AST/ALT \> 5 times the upper limit of normal (ULN)
* total bilirubin\> 2.5 times ULN
* BUN/Ccr \> 3 times ULN
* HIV positive patient
* Patient has a history of hypersensitivity, or any serious reaction to any component of this product or other echinocandins.
* Patient has a life expectancy of \<1 month
* Subject is unlikely to comply with the visits scheduled in the protocol in the opinion of investigator or has a history of non-compliance.
* Pregnant women, nursing mothers, lactating women, and women of child-bearing potential who are unwilling to use reliable contraception for the duration of the study and for 6 weeks following completion of the study.
* Patient has been previously enrolled in this study.
Belgian Central Sleep Apnea REgistry

This study evaluates different factors that determine the treatment choice and treatment compliance in patients with central sleep apnea. All patients will receive routine care (registry).

Central sleep apnea (CSA) is characterized by intermittent cessation or decrease of airflow and effort of breathing during sleep. The diagnostic criteria for CSA varies according to the type of CSA (e.g. CSA due to cardiac failure, due to a medication, ...).

CSA is defined as: (1) an apnea/hypopnea index ≥ 15 per hour of sleep and (2) the number of central apneas and/or hypopneas is \> 50% of the total number of apneas and hypopneas.

Presence of CSA is associated with excessive daytime sleepiness and poor sleep quality. Furthermore, in patients with heart failure, presence of CSA was found to be related to mortality. As yet, however, there is insufficient knowledge on the clinical features, pathophysiological background and consecutive algorithms for treatment. Currently, it is not fully clear whether CSA or the treatment of CSA is related to disease progress.

The aim of this trial is to evaluate the current treatment choices for CSA in Belgium and compliance with and effects of these treatments.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old
* An apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events \> 50%, derived from polysomnography (diagnostic or during (PAP) treatment)
* Written informed consent provided

Exclusion Criteria:

- Patients with mental disability making it impossible to understand the study protocol
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective disorder.

This is a Phase 2, open-label, dose titration study to assess the efficacy and safety of three once daily (q.d.) doses (12.5, 25, and 50 mg) of NBI-98854 administered once daily for up to 12 days consisting of three treatment periods of 4 days each (Periods 1, 2, and 3). The starting dose will be 12.5 mg q.d. (Period 1), and this dose will be escalated to 25 mg q.d. (Period 2) and then to 50 mg q.d. (Period 3) based upon each subject's ability to tolerate NBI-98854. Progression to the next dose level will be based upon the subject's ability to tolerate the previous dose and the Investigator's review of adverse events and safety data. For subjects who do not tolerate a dose increase, the dose may be decreased to the dose that was previously administered (i.e., 25 mg to 12.5 mg, 50 mg to 25 mg) and continued at that dose for the remainder of the study treatment. Up to 10 medically stable subjects with schizophrenia or schizoaffective disorder who have moderate or severe symptoms of TD will be enrolled as outpatients.

Eligibility Criteria:
Inclusion Criteria:

* Males or females (non-childbearing potential) aged 18 to 65 years (both inclusive).
* Have moderate or severe Tardive Dyskinesia symptoms (Total AIMS score of at least 9)
* Have a clinical diagnosis of schizophrenia or schizoaffective disorder.
* Receiving a stable dose of antipsychotic medication for a minimum of 30 days or have stable psychiatric status.
* Doses of concurrent medications and the conditions being treated have been stable for a minimum of 30 days and expected to remain stable during the study.
* Are in good general health and expected to complete the clinical study as designed.
* Have a body mass index (BMI) of 18 to 38 kg/m\^2.
* Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion Criteria:

* Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening.
* Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start.
* Have a known history of neuroleptic malignant syndrome.
* Have a significant risk of suicidal or violent behavior.
* Receiving medication for the treatment of Tardive Dyskinesia
* Receiving any excluded concomitant medication as specified in the protocol.